| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer
1 company
Behrad Derakhshan is Chief Business Officer at EWTX. Behrad Derakhshan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
Our model assigns Behrad Derakhshan a middling insider score of 50/100, based on 9 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -35.8%.
The EWTX filings lean toward selling, a net 74,815 shares.
Behrad Derakhshan has 14 Form 4 filings on record from August 2021 to August 2026, all as Chief Business Officer at Edgewise Therapeutics (EWTX), 2021–2026.
The 35 reported transactions were 13 open-market sales, 11 option exercises and 11 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 8 sales worth about $2.1M.
The largest open-market sale was 42,068 shares of EWTX at an average $29.03 on September 20, 2024, about $1.2M. Twelve months later EWTX was down 50%.
1 of the 8 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 5,100 | $43.81 | $223,424.05 | -13.8% | - | - | |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 2,491 | $13.39 | $33,360.47 | -9.5% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 1,691 | $16.45 | $27,824.05 | -7.7% | -15.7% | +81.0% | |
| Feb 5, 2025 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 10,000 | $30.03 | $300,300.00 | -37.3% | -52.1% | -9.5% | |
| Sep 20, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 42,068 | $29.03 | $1,221,133.08 | -73.6% | +8.9% | -49.6% | |
| May 2, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 1,718 | $18.91 | $32,487.38 | -11.3% | -11.7% | -12.3% | |
| Feb 9, 2024 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE10b5-1 | 10,000 | $20.03 | $200,258.04 | -58.8% | +2.7% | +35.4% | |
| May 2, 2023 | EWTX Edgewise Therapeutics, Inc. | Chief Business Officer | Sale+OE | 1,747 | $8.90 | $15,556.86 | -19.9% | -16.7% | +117.3% |